(Q34771798)

4 August 2017

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis (English)

1 reference

4 August 2017

0 references

T Vollmer

1

1 reference

4 August 2017

H Panitch

2

1 reference

4 August 2017

A Bar-Or

3

1 reference

4 August 2017

J Dunn

4

1 reference

4 August 2017

M S Freedman

5

1 reference

4 August 2017

S K Gazda

6

1 reference

4 August 2017

D Campagnolo

7

1 reference

4 August 2017

F Deutsch

8

1 reference

4 August 2017

D L Arnold

9

1 reference

4 August 2017

18 April 2008

1 reference

Multiple Sclerosis Journal

4 August 2017

1 reference

4 August 2017

14

1 reference

4 August 2017

663-670

1 reference

4 August 2017

5

1 reference

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

4 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

Glatiramer acetate for the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

Evidence for neuroprotection and remyelination using imaging techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

A sharper Bonferroni procedure for multiple tests of significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

Immunopathogenesis and immunotherapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

The effect of immunosuppressive protocols on spontaneous CNS remyelination following toxin-induced demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

Mechanism of action of mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507085759

21 January 2018

Identifiers

DOI

10.1177/1352458507085759

1 reference

4 August 2017

1 reference